'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T